Anthem Biosciences Limited
₹828.45-₹2.55 (-0.3%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹35,376 Cr
- P/E
- 66.2x
- EV / EBITDA
- 61.4x
- Revenue
- ₹1,841 Cr
- Net margin
- 26.4%
- ROCE
- 24.0%
Price chart
Technical chartScreen technicals →+15.5% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -3.4%
- 3M
- +5.7%
- 6M
- +9.0%
- 1Y
- +15.5%
- 5Y
- +9.5%
52-week range
Day change -₹2.55 (-0.3%) from ₹831 to ₹828 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in ANTHEM, bought on each weekday since 2025.
AI Summary
Indian StockStrengths1
- Strong 5-year revenue CAGR of 17.5%
Concerns0
Rule-based from financial data. Not advice.
About the company
Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients.
Read moreShow less
Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry. It also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2; microbial and mammalian biosimilars; probiotics, such as bacillus species, lactobacillus species, bifidobacterium species, streptococcus species and saccharomyces boulardii; enzymes; peptides, including semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide; nutritional actives, vitamin analogues, and APIs. The company was incorporated in 2006 and is based in Bengaluru, India.
- Sector
- Healthcare
- Shares outstanding
- 56.2 Cr shares
- ISIN
- INE0CZ201020
- BSE code
- 544449
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹35,376 Cr
- P/E
- 66.2x
- P/B
- 12.4x
- EV / EBITDA
- 61.4x
- EV / Sales
- 24.9x
- P/S
- 24.9x
- Earnings yield
- 1.5%
- 52-week high
- ₹957.80
- 52-week low
- ₹592.05
Profitability
- Operating margin
- 35.6%
- Net margin
- 26.4%
- EBITDA margin
- 40.6%
- ROE
- 19.4%
- ROCE
- 24.0%
- ROA
- 16.1%
- Dividend payout
- 0.0%
- Tax rate
- 23.0%
- Other income, % of PBT
- 14.4%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,841 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 29.8%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 17.5%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹575 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 0.9%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 34.9%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 32.2%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹164 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -48.6%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹159 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 16.6%
Solvency and efficiency
- Current ratio
- 7.72
- Debt / Equity
- 0.09
- Debt / Assets
- 0.07
- Debt / EBITDA
- 0.30
- Interest coverage
- 56.11
- Financial leverage
- 1.20
- CFO / Net profit
- 0.44
- Cash / Market cap
- 3.4%
- Cash per share
- ₹21.71
- Asset turnover
- 0.61
- Fixed asset turnover
- 2.97
- Capital intensity
- 0.34
- Debtor days
- 126 days
- Inventory turnover
- 2.83
- Cash conversion cycle
- 194 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹27 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹1,151 Cr |
| Sales | Operating profit | ₹690 Cr |
| Operating profit | Interest | ₹9 Cr |
| Operating profit | Depreciation | ₹78 Cr |
| Operating profit | Profit before tax | ₹603 Cr |
| Other income | Profit before tax | ₹109 Cr |
| Profit before tax | Tax and other | ₹205 Cr |
| Profit before tax | Net profit | ₹506 Cr |
Revenue and net profit
Revenue grew 29.8% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹1,103 Cr | ₹271 Cr |
| FY2022 | ₹1,231 Cr | ₹406 Cr |
| FY2023 | ₹1,057 Cr | ₹386 Cr |
| FY2024 | ₹1,418 Cr | ₹375 Cr |
| FY2025 | ₹1,841 Cr | ₹506 Cr |
Cash flows
FY2025: ₹440 Cr from operations, ₹194 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹278 Cr | ₹82 Cr |
| FY2022 | ₹333 Cr | ₹127 Cr |
| FY2023 | ₹319 Cr | -₹59 Cr |
| FY2024 | ₹164 Cr | -₹28 Cr |
| FY2025 | ₹440 Cr | ₹194 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹1,841 Cr+29.8%1Y
- Net profit
- ₹506 Cr+34.9%1Y
- Cash from operations
- ₹440 Cr
- Free cash flow
- ₹194 Cr
- Revenue CAGR, 5Y
- 17.5%
- EBITDA CAGR, 5Y
- 23.1%
- Net profit CAGR, 5Y
- 32.2%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,841 Cr | ₹690 Cr | — | ₹506 Cr | ₹440 Cr | ₹194 Cr | 20.5% | +29.8% | +34.9% |
Monthly returns
Month-by-month returns of ANTHEM across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹2,836 Cr |
| Equity capital | ₹112 Cr |
| Reserves | ₹2,361 Cr |
| Borrowings | ₹113 Cr |
| Other liabilities | ₹249 Cr |
| Assets | ₹2,836 Cr |
| Fixed assets | ₹624 Cr |
| Capital work in progress | ₹58 Cr |
| Investments | ₹533 Cr |
| Other assets | ₹1,620 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
ANTHEM trades at 66.2x earnings against a peer median of 52.6x (a 26% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Anthem Biosciences LimitedANTHEMthis companyP/E ↑ premium | ₹35,376 Cr | 66.2x | 12.4x | 19.4% | 61.4x |
| Procter & Gamble Hygiene & Health Care Ltd.PGHH | ₹40,121 Cr | 48.5x | 43.1x | — | — |
| GlaxoSmithkline Pharmaceuticals Ltd.GLAXO | ₹40,108 Cr | 42.4x | 23.5x | — | — |
| Narayana Hrudayalaya LimitedNH | ₹38,566 Cr | 83.0x | 16.6x | 23.1% | 54.0x |
| Ipca Laboratories Ltd.IPCALAB | ₹38,240 Cr | 39.5x | 5.2x | 8.3% | 32.5x |
| Ajanta Pharma Ltd.AJANTPHARM | ₹34,058 Cr | 35.8x | 8.3x | 23.6% | 27.3x |
| Global Health LimitedMEDANTA | ₹31,404 Cr | 59.8x | 8.3x | 16.0% | 37.3x |
| Aster DM Healthcare LimitedASTERDM | ₹31,356 Cr | 92.8x | 7.1x | 5.4% | 78.2x |
| Emcure Pharmaceuticals LimitedEMCURE | ₹29,399 Cr | 67.9x | 9.1x | 8.3% | 53.5x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
ANTHEM since 1 January, against earlier years.
Historical volatility
ANTHEM's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 37.0% |
| FY2022 | 46.0% |
| FY2023 | 41.0% |
| FY2024 | 36.0% |
| FY2025 | 37.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹1,841 Cr |
| Costs | |
| Interest | ₹9 Cr |
| Expenses | ₹1,151 Cr |
| Operating profitOperating Profit | ₹690 Cr |
| Other income and charges | |
| Profit before tax | ₹711 Cr |
| Tax | |
| Net profitNet Profit | ₹506 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹2,836 Cr |
| Equity capitalEquity Capital | ₹112 Cr |
| Reserves | ₹2,361 Cr |
| Borrowings | ₹113 Cr |
| Other liabilitiesOther Liabilities | ₹249 Cr |
| AssetsTotal Assets | ₹2,836 Cr |
| Fixed assetsFixed Assets | ₹624 Cr |
| Capital work in progressCWIP | ₹58 Cr |
| Investments | ₹533 Cr |
| Other assetsOther Assets | ₹1,620 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹440 Cr |
| Investing cash flowCash from Investing Activity | -₹246 Cr |
| Financing cash flowCash from Financing Activity | -₹66 Cr |
| Change in cashNet Cash Flow | ₹127 Cr |
Learn while you research
Academy chapters picked for Anthem Biosciences Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 66.2, learn when high multiples are justified.6 min read
- 04 Growth Investing30% revenue growth is in the top tier, learn how to value growth.7 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read